Tenon Medical Inc (TNON) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Tenon Medical Inc stock (TNON) is currently trading at $0.78. Tenon Medical Inc PS ratio (Price-to-Sales) is 2.73. Analyst consensus price target for TNON is $2.75. WallStSmart rates TNON as Sell.
- TNON PE ratio analysis and historical PE chart
- TNON PS ratio (Price-to-Sales) history and trend
- TNON intrinsic value — DCF, Graham Number, EPV models
- TNON stock price prediction 2025 2026 2027 2028 2029 2030
- TNON fair value vs current price
- TNON insider transactions and insider buying
- Is TNON undervalued or overvalued?
- Tenon Medical Inc financial analysis — revenue, earnings, cash flow
- TNON Piotroski F-Score and Altman Z-Score
- TNON analyst price target and Smart Rating
Tenon Medical Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Tenon Medical Inc (TNON) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Tenon Medical Inc (TNON) Key Strengths (1)
Revenue surging 32.20% year-over-year
Supporting Valuation Data
Tenon Medical Inc (TNON) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Very expensive at 5.2x book value
Very low institutional interest at 3.99%
Micro-cap company with very limited liquidity and high volatility
Revenue is fairly priced at 2.73x sales
Tenon Medical Inc (TNON) Detailed Analysis Report
Overall Assessment
This company scores 24/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 1 register as strengths (avg 10.0/10) while 6 fall into concern territory (avg 2.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth. Growth metrics are encouraging with Revenue Growth at 32.20%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Price/Book. Some valuation metrics including Price/Sales (2.73), Price/Book (5.16) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -197.30%, Operating Margin at -222.80%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -197.30% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 32.20% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
TNON Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
TNON's Price-to-Sales ratio of 2.73x sits near its historical average of 2.79x (29th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 9% below its historical high of 3x set in Mar 2026, and 4% above its historical low of 2.63x in Mar 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for Tenon Medical Inc (TNON) · HEALTHCARE › MEDICAL DEVICES
The Big Picture
Tenon Medical Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 3M with 32% growth year-over-year.
Key Findings
Revenue growing at 32% YoY, reaching 3M. This pace significantly outperforms most MEDICAL DEVICES peers.
Free cash flow is -4M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Tenon Medical Inc maintain 32%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact Tenon Medical Inc.
Bottom Line
Tenon Medical Inc is a high-conviction growth story with revenue accelerating at 32% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 0.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 10:09:49 AM
About Tenon Medical Inc(TNON)
NASDAQ
HEALTHCARE
MEDICAL DEVICES
USA
Tenon Medical, Inc., a medical device company, develops surgical implant systems to optimize sacroiliac joint fixation/fusion surgery and outcomes. The company is headquartered in Los Gatos, California.